tirzepatide surmount 5 more effective in blood sugar control and body weight loss than semaglutide SURMOUNT-5: Tirzepatide and semaglutide go

Discussion Our research aimed to design and perform computational analysis of the fusion proteins with high affinity and specificity for human serum albumin and a protease-resistant GLP-1 peptide to produce potent GLP-1 agonists with an extended plasma half-life for the treatment of type 2 diabetes

Standards of Medical Care in Diabetes 2026

Those transitioning off prescription GLP-1 medications

Tirzepatide commonly causes nausea (15-25%), diarrhea (12-23%), vomiting (8-11%), constipation (11-17%), and abdominal discomfort, particularly during dose escalation, according to FDA labeling

High vantage points can also help with visibility

STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies